Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis
Table 1
Effect of metformin or sitagliptin on DOX-induced cardiotoxicity in rats.
Parameter
Control
Metformin
Sitagliptin
DOX
Metformin/DOX
Sitagliptin/DOX
Heart/body weight ratio (mg/g)
2.91 ± 0.04
3.08 ± 0.09
2.85 ± 0.1
2.96 ± 0.01
2.86 ± 0.05
3.1 ± 0.07
LDH (IU/L)
469.12 ± 4.91
427.82 ± 4.26
448.48 ± 5.62
2199.3 ± 33.25
666.7 ± 10.88
1171.9 ± 19.47
CK-MB (IU/L)
537.98 ± 3.9
506.2 ± 5.05
518.72 ± 5.58
2632.78 ± 53.29
715.1 ± 31.84
1021.97 ± 27.3
MDA (nmol/g tissue)
28.7 ± 0.54
27.68 ± 0.41
28.63 ± 0.43
70.77 ± 1.22
50.9 ± 0.87
54.85 ± 1.28
(nmol/g tissue)
127.47 ± 0.77
157.48 ± 1.61
126.71 ± 0.84
304.36 ± 6.45
228.87 ± 7.72
213.26 ± 5.95
SOD (U/mg tissue)
0.88 ± 0.04
0.89 ± 0.04
0.89 ± 0.04
0.39 ± 0.04
0.74 ± 0.04
0.59 ± 0.03
LDH: lactate dehydrogenase; CK-MB: creatine kinase-MB isoenzyme; MDA: malondialdehyde; : total nitrites and nitrates; SOD: superoxide dismutase. Results are expressed as mean ± SEM of six observations. Significantly different from control group (). Significantly different from DOX group ().
